CRM Neutral Rating Maintained by UBS May 2026

Salesforce maintains its Neutral rating from UBS as the analyst firm adjusts expectations for the cloud software giant. On May 21, UBS lowered its price target to $185 from $200, signaling caution despite the company’s strong market position. The Salesforce neutral rating reflects mixed sentiment across Wall Street, where 35 analysts rate the stock as a Buy while 10 suggest holding. With a market cap of $167.5 billion, CRM trades at $176.31, down 2.1% today.

UBS Adjusts Price Target on Salesforce Neutral Rating

UBS maintained its Neutral stance on Salesforce while trimming its price target by $15 per share. The analyst firm cited valuation concerns and near-term headwinds as reasons for the adjustment. UBS lowered the price target to $185 from $200, suggesting limited upside from current levels.

The Salesforce neutral rating reflects a balanced view of the company’s prospects. While UBS acknowledges strong fundamentals, the firm sees limited catalysts for near-term gains. This cautious stance contrasts with the broader analyst consensus, where Buy ratings outnumber Holds by more than three to one.

Financial Metrics Show Mixed Signals for CRM Stock

Salesforce trades at a P/E ratio of 22.1x with a price-to-sales ratio of 4.0x, both elevated for the software sector. The company generates $44.41 in revenue per share and $7.98 in net income per share on a trailing basis. Free cash flow remains robust at $15.40 per share, supporting the company’s dividend of $1.69 annually.

Growth metrics paint a stronger picture. Net income surged 49.8% year-over-year, while earnings per share jumped 51.5%. Operating cash flow grew 27.9%, demonstrating operational strength. However, the stock trades 21% below its 50-day average of $182.69 and 21% below its 200-day average of $223.08, reflecting recent weakness.

Analyst Consensus Leans Bullish Despite Neutral Call

Wall Street remains largely optimistic on Salesforce stock, with 35 Buy ratings against just 10 Holds and 2 Sells. The consensus score of 3.0 indicates a Buy recommendation overall. Meyka AI rates CRM with a grade of A, reflecting strong fundamentals and growth prospects.

This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The disconnect between UBS’s Neutral stance and the broader bullish consensus suggests divergent views on valuation. Earnings are due May 27, which could provide clarity on the company’s trajectory and validate or challenge current price targets.

Technical Setup and Valuation Concerns

CRM’s technical picture shows weakness with the RSI at 47.3, indicating neutral momentum. The stock sits near the middle of its Bollinger Bands, suggesting consolidation. Volume remains below average at 10.9 million shares, down from the 13.6 million daily average.

Valuation concerns drive the Salesforce neutral rating. At 2.78x price-to-book, the stock commands a premium to many peers. The debt-to-equity ratio of 0.29x remains healthy, but the current ratio of 0.76x signals tight working capital. UBS’s price target implies 4.8% downside from current levels, reflecting the firm’s cautious near-term outlook.

Final Thoughts

UBS’s maintained Neutral rating on Salesforce reflects a balanced but cautious view of the software leader. The $15 price target reduction signals valuation concerns despite strong earnings growth and cash generation. While the broader analyst community remains bullish, UBS’s conservative stance highlights the tension between Salesforce’s operational strength and elevated valuations. Investors should monitor the May 27 earnings report for guidance on growth sustainability. The Salesforce neutral rating suggests waiting for better entry points rather than aggressive buying at current levels.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.